

Table SI. Baseline demographic and disease characteristics (all randomized patients)

	ESTEEM 1		ESTEEM 2	
	Placebo n=282	Apremilast 30 mg BID n=562	Placebo n=137	Apremilast 30 mg BID n=274
Age, years, mean (SD)	46.5 (12.7)	45.8 (13.1)	45.7 (13.4)	45.3 (13.1)
Male, n (%)	194 (68.8)	379 (67.4)	100 (73.0)	176 (64.2)
White, n (%)	250 (88.7)	507 (90.2)	128 (93.4)	250 (91.2)
Body mass index, kg/m ² , mean (SD)	31.3 (7.4)	31.2 (6.7)	30.7 (7.1)	30.9 (6.7)
Duration of plaque psoriasis, years, mean (SD)	18.7 (12.4)	19.8 (13.0)	18.7 (12.1)	17.9 (11.4)
Psoriasis Area and Severity Index score, mean (SD)	19.4 (7.4)	18.7 (7.2)	20.0 (8.0)	18.9 (7.1)
Psoriasis Area and Severity Index score >20, n (%)	87 (30.9)	158 (28.1)	49 (35.8)	81 (29.6)
Body surface area, %, mean (SD)	25.3 (14.6)	24.4 (14.7)	27.6 (15.8)	25.5 (15.4)
Body surface area >20%, n (%)	149 (52.8)	266 (47.3)	80 (58.4)	143 (52.2)
Static Physician Global Assessment of 4 (severe), n (%)	89 (31.6)	161 (28.6)	49 (35.8)	75 (27.4)
Pruritus (0–100 mm VAS), mean (SD)	65.2 (24.8)	66.2 (25.5)	65.0 (26.0)	67.8 (25.2)
Skin discomfort/pain (0–100 mm VAS), mean (SD)	57.1 (29.7)	58.1 (29.3)	56.9 (28.9)	58.9 (28.9)
Patient global assessment of psoriasis disease activity VAS (0–100 mm), mean (SD)	49.6 (26.95)	50.1 (27.62)	50.4 (28.22)	52.4 (27.40)
Dermatology Life Quality Index score, mean (SD)	12.2 (6.7)	12.7 (7.1)	12.8 (7.0)	12.6 (7.2)
Prior conventional systemic therapy, n (%)	102 (36.2)	212 (37.7)	53 (38.7)	106 (38.7)
Prior biologic therapy, n (%)	80 (28.4)	162 (28.8)	44 (32.1)	92 (33.6)

The n reflects the number of randomized patients; actual number of patients available for each parameter may vary. Pruritus and skin discomfort/pain visual analog scale (VAS) (mm) and patient global assessment of psoriasis disease activity VAS values were based on patients with a non-zero baseline value (ESTEEM 1 and 2, placebo n=277, n=133, apremilast 30 mg BID, n=559, n=268, respectively).